Jody Staggs: Yes, I think we’re, we’re pretty well done here. I was looking at this before. 2022, we had a lot of onetime costs, there was a lot of legal costs and separation costs and things, right. I think I would say, I’m looking at our G&A number, maybe it’s something in the $8 million a year, I think, would be more than enough. So it’s not really going to move a lot versus what it has been talking about adding, three to four €“ I guess four investment professionals over the years. You could probably figure out what those people typically earn in the Dallas market. So I was sort of, I think, first quarter 2023, we’ll be able to kind of show you what the runway run rate is. The 2022 was extremely lumpy with a lot of onetime costs. And it’s a little bit hard to hard to say, but it’s going to be in that kind of $7 million to $8 million range, I think on a go-forward basis.
Unidentified Analyst: And then my final thing is I say, keep buying back stock. Thank you for that. But looks like they’re going to keep presenting your opportunity.
Jody Staggs: Yes, I appreciate that. We’ve been a little frustrated. We cannot lie that, there’s rules in this 10b5 program with the algorithm and with the trailing volume. So we are, we’ve got a lot smarter on the 10b5 and 10b18. And we’re hopeful that going forward, we can do a bit better there. But now, yes, at these prices, we think it’s a great use accountable.
Unidentified Analyst: Great, thanks.
Operator: Our next question comes from William Kok from another private investor. Please, William, go ahead.
Unidentified Analyst: Good morning, everybody. This is Bill Couch . I own some, some shares, I live in Connecticut. I was wondering if you have any idea what the potential annual revenues for an oral leuprolide drug would be?
Jody Staggs: Hey, Bill, thanks for the question. I think, I do get a call. I get questions on this periodically. I think one thing that I would just sort of state is this is not we’re not studying for broad women’s health conditions, uterine fibroids or endometriosis. Leuprolide is a GnRH agonist. And this is kind of the Gen 1 version of treating these conditions. And that market has moved on to the 2.0, which is the antagonist. And if you look at like a relagolics that is really where that market has gone. So this is not a billion dollar type opportunity. The indication we’re studying for is we think it’s pretty interesting. It is sort of a semi rare pediatric indication. It’s not rare, it’s probably not an orphan. But the market we’ve looked at is, it’s going to be in the low hundreds of millions of dollars type opportunity.
Unidentified Analyst: Thank you.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Jody Staggs. Please go ahead with any closing remarks.
Jody Staggs: Yes, thanks for everyone joining the call. Thanks for the questions and you can please reach out to myself or Yvette with anything else and hope everyone has a great day.
Operator: And this concludes the conference. Thank you for attending today’s presentation. You may now disconnect.
